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Abstract 
Objective: Aim of this prospective longitudinal study was to identify static and dynamic 
O-(2-[18F]fluorethyl)-L-tyrosine PET (18FET-PET) derived imaging biomarkers in 
glioblastoma (GBM) patients. 
Patients and Methods: 79 patients with newly diagnosed GBM were included; 42 
patients underwent stereotactic biopsy (unresectable tumors) and 37 patients 
microsurgical tumor resection. All patients were scheduled to receive radiotherapy 
plus concomitant and adjuvant temozolomide (RCx/TMZ). 18FET-PET evaluation using 
static and dynamic analysis was done prior to biopsy/resection, after resection, 4-6 
weeks following RCx and after three cycles of TMZ. Endpoints were survival and 
progression-free-survival. Prognostic factors were obtained from proportional hazards 
models.  
Results: Biological tumor volume before RCx (BTVpreRCx) was the most 
important 18FET-PET derived imaging biomarker and was independent of MGMT 
promoter methylation and clinical prognostic factors: patients with smaller BTVpreRCx 
had significantly longer progression free (PFS) and overall survival (OS). 18FET time 
activity curves (TAC) before treatment and their changes after RCx were also related 
to outcome, patients with initially increasing TAC experienced longer overall survival. 
Conclusion: BTVpreRCx and TAC represent important 18FET-PET-derived imaging 
biomarkers in GBM. Increasing TAC are associated with prolonged OS. The BTVpreRCx 
is a strong prognostic factor for PFS and OS independent of the mode of surgery. Our 
data furthermore suggest that patients harbouring resectable GBM might benefit from 
maximal PET-guided tumor resection.  
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 Abbreviations: BG, background; BTV, biological tumor volume; CT, computed 
tomography, 18FET-PET, O-(2-[18F]fluorethyl)-L-tyrosine positron emission 
tomography; FLAIR, fluid-attenuated inversion recovery; GBM, glioblastoma; Gd 
gadolinium; Gd+, gadolinium enhanced; HR, hazard ratio; KPS, Karnofsky 
performance score; LBR, Lesion to brain ratio, MGMT, O6-methylguanyl-DNA-
methyltransferase; MRI, magnetic resonance imaging; OS, overall survival; PCR, 
polymerase chain reaction; PFS, progression-free survival; ROC, receiver operating 
characteristics; RCx, radio/chemotherapy; ROI, region of interest; RT, radiotherapy; 
SN, sensitivity; SP, specificity; TAC, time activity curve; TMZ, temozolomide, VOI, 
volume of interest. 
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Introduction 
 
Glioblastoma (GBM) is a fatal intrinsic brain tumor with median survival times of 11-15 
months1. Current standard of care includes resection in combination with radiotherapy 
plus concomitant (RCx) and adjuvant chemotherapy using temozolomide (RCx/TMZ)2. 
Evaluation of imaging biomarkers derived from positron emission tomography (PET) 
and MRI might improve prognostic evaluation, adjustment of treatment strategies and 
monitoring of treatment response3-5. So far, PET is mainly used in the setting of 
differential-diagnosis of suspected gliomas, identification of anaplasia or malignant 
progression6, 7. In addition, it could modify/improve radiation treatment planning in 
combination with MRI8. Retrospective data have indicated that the biologically tumor 
volume (BTV) before radiation therapy as defined by amino-acid PET might correlate 
with poor outcome in glioblastoma patients: Those with smaller BTVs before radiation 
did significantly better9. The current prospective study was conducted to elucidate the 
prognostic relevance of BTV before radiation plus concomitant TMZ as defined by 
18FET-PET. It was planned to include two patient cohorts of similar size either 
undergoing biopsy only or tumor resection. Patients with resectable tumors were 
considered candidates for microsurgery, whereas patients with eloquent tumor 
location were candidates for biopsy only. All patients were intended to receive 
RCx/TMZ according to the EORTC/NCIC protocol2. Our hypothesis was that BTV 
before concomitant radio-chemotherapy would be a prognostic/predictive factor 
independent of the mode of the surgical procedure. Beyond that primary aim of the 
study, we performed an explorative analysis of static and dynamic PET variables 
before/after treatment and their possible correlations with outcome.  
 
 
Patients and Methods 
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 Study design 
This prospective longitudinal multicenter study (www.clinicaltrials.gov NCT01089868) 
was performed within the context of the German Glioma Network (GGN), a non-
interventional consortional prospective study funded by the German Cancer Aid 
(Deutsche Krebshilfe, 70-3163-Wi 3) (www.gliomnetzwerk.de). Adult patients were 
eligible if they had a supratentorial GBM with histology being proven by stereotactic 
biopsy or open tumor resection, no prior history of surgery, radiotherapy or 
chemotherapy, and a Karnofsky performance score (KPS) ≥70. Exclusion criteria were 
pregnancy and inability to undergo MRI or 18FET-PET for any reason. Resectable 
tumors received microsurgical resection (cohort A) and unresectable tumors 
stereotactic biopsy (cohort B). All patients were scheduled to undergo RCx/TMZ 
according to the EORTC/NCIC protocol2 and to have 18FET-PET preoperatively, 
postoperatively (cohort A only), at 4-6 weeks after RCx in analogy to MRI, and after 
the first three cycles of adjuvant TMZ (Supplemental Fig. e-1). MRI and PET were 
obtained at the same time points with the specification that the postoperative MRI 
performed in cohort A was scheduled within the first 72 h after surgery. The study was 
designed to elucidate in particular the prognostic role of BTV. We planned to include at 
least 72 patients equally distributed in both cohorts. Given an accrual period of 36 
months and a follow-up time of three years, this sample size would allow identifying 
biomarkers exhibiting a hazard ratio of 2 or higher with a statistical power of 80%. 
Additionally, the study explored the prognostic relevance of dynamic 18FET-PET-
derived biomarkers. Power calculation, however, did not refer to these analyses. 
Inclusion period was from 02/2007 until 01/2010, date of last follow-up evaluation was 
February 28th 2014. Primary endpoint was overall survival (OS), secondary end point 
was progression-free survival (PFS). 
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Standard Protocol Apprrovals, Registrations and Patient Consents 
All patients gave written informed consent, and the prospective study protocol was 
approved by the institutional review board (IRB) of the Ludwig Maximilians University, 
Munich, Germany (AZ 216/04) as well as the IRB of participating sites. 
 
MRI protocol 
MRI was performed at the above-mentioned time-points on 1.5 or 3.0 Tesla scanners 
(Philips Intera 3T, Andover, MA, USA and Signa HDxt, GE Healthcare, Milwaukee, WI, 
USA). The standardized sequence protocol comprised an axial diffusion-weighted, an 
axial T2-weighted, an axial fluid-attenuated inversion recovery (FLAIR) sequence, and 
isovoxel (3D) T1-weighted gradient-echo sequences. Two experienced 
neuroradiologists (J.L., H.J), blinded for the results of 18FET-PET investigations, 
evaluated the MRI scans including volumetric analyses of each tumor under 
investigation. For a detailed description of the MRI protocol please see supplemental 
part. 
18FET-PET protocol 
Fifty minute-long dynamic emission recording was initiated after injection of 
approximately 180 MBq 18FET with either a stand-alone PET (EACT EXACT HR+) or a 
PET/CT (Biograph) scanner (Siemens Medical Systems) according to a standardized 
acquisition protocol. Semi-quantitative PET data assessment included the maximal 
standardized uptake value of the tumor corrected for the mean background activity in 
the healthy contralateral hemisphere reflecting the lesion-to-brain ratio (LBRmax) and 
the estimated biological tumor volume (BTV) defined by semi-automatic threshold-
based calculation of a volume of interest (VOI; LBR ≥ 1.8). As previous studies have 
reported 1.6 as optimal cut-off for untreated glioma10 and a cut-off value of 2.0 for pre-
treated glioma11, we considered a threshold of 1.8 to be most appropriate for 
longitudinal assessment of GBM before and after therapy.   
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Evaluation of dynamic PET recordings was assessed according to our standardized 
procedure6. Resulting time-activity-curves (TAC) were classified into two groups: i) 
decreasing TAC with SUV showing an early peak within the first 20 min followed by a 
constant descent thereafter or ii) increasing TAC with SUV constantly ascending or 
followed by a plateau (for further details, see supplement (Appendix e-1)). 
 
Histology and MGMT analysis 
Histological diagnosis was made centrally (H.K.) according to the WHO classification 
12. MGMT analysis was performed using methylation-specific PCR13. 
 
Statistical analysis 
Reference point of the study was the date of surgery. Endpoints were death and date 
of tumor progression. All patient files were reviewed centrally (JCT and MW). 
Statistical analysis was performed using the SPSS 17.0 software package. PFS and 
OS were analysed by the Kaplan-Meier method. Comparison of survival curves was 
done with the two-sided log rank test. Categorical variables were analyzed with the 
chi-square and continuously scaled variables with the Wilcoxon test. Wilcoxon test for 
related samples was used to analyze changes of static/dynamic FET-measures over 
time. Correlation between continuously scaled variables was described with Pearson’s 
correlation coefficient. Potential prognostic factors were identified using proportional 
hazards models. Parameters which were significant in univariate analyses were 
included in multivariate models. The optimized model contained only variables that 
were significantly associated with the endpoint of interest after adjustment for the 
effects of other variables included in the model. Receiver operating-characteristic 
(ROC) curve analysis identified cut-off values of continuously scaled imaging 
biomarkers of interest.  
 
 8 
Results 
Study population  
92 patients were screened for study entry, 79 patients fulfilled the inclusion criteria 
(Supplemental Fig. e-2): 42 were assigned to cohort A (resection) and 37 to cohort B 
(biopsy). Age, initial KPS, gender distribution, the frequency of MGMT promoter 
methylation and the applied treatment did not differ in both cohorts. Patient 
characteristics are summarized in (Supplemental Tab.e-1). 
On the date of last follow-up, 70 patients had died (37 in cohort A, 33 in cohort B). Two 
deaths were not GBM-associated and handled as censored events at the time of their 
last follow up. Two patients were lost to follow-up. 5 patients are still alive (median 
follow-up: 48.6 months). 76 patients experienced tumor progression (40 patients in 
cohort A and 36 patients in cohort B). 64 patients underwent a complete course of 
RCx, 12 patients did not undergo RCx for various reasons, and in 3 patients RCx was 
disrupted because of progressive clinical deterioration. 31 patients received 3 cycles 
of TMZ and thus completed the PET study protocol as planned. The frequency of 
incomplete or not begun RTCx course was slightly higher in the biopsy group (14 vs 
24%, p=0.5). Overall, median PFS was 7.6 months (95 CI % 4.2-11.0) and median OS 
was 13.5 months (95%CI 10.9-16.7). PFS and OS did not differ significantly between 
both cohorts. In those undergoing a complete course of RCx, however, OS was longer 
after surgery than after biopsy (median OS: 16.7 vs. 13.4, p=0.02). 
Median initial BTV was 23.8 ccm, median initial LBRmax was 3.6; nearly identical 
values were seen in both cohorts (Table 1). Initial TAC was decreasing in 59/74 
tumors and increasing in 15/74 tumors. In five tumors, TAC data were not available.  
MRI-based volumetric estimations of the Gd+volume including necrotic/cystic areas 
and the Gd+volume alone were 35.7 ccm (median) and 13.5 ccm, respectively, while 
T2/FLAIR volume accounted for 75.0 ccm. The volume distibution was as follows: 
T2/FLAIR > Gd+volume including necrotic/cystic parts > BTV > Gd+ volume alone. 
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 BTV before RCx 
Initial BTV gained prognostic relevance for OS in the biopsy group (p=0.002): Those 
with smaller BTV did better. In the surgery group, BTV was associated with outcome 
only after surgery (OS: p=0.002; PFS: p=0.02). In order to determine the potential 
significance of BTV and SUVmax/BG before RCx (BTVpreRCx and SUVmax/BGpreRCx, Tab. 
1), post-surgical values of cohort A and the initial values of cohort B were analysed 
together. BTV before radiotherapy (referred to as BTVpreRCx in the following) showed a 
strong association with survival. According to ROC analyses, the cut-point of BTVpreRCx 
was estimated to be 9.5 ccm (sensitivity (SN): 64%; specificity (SP) 70%). Median OS 
(PFS) for those with a BTVpreRCx  below 9.5 ccm was 17.5 (8.8) months and 10.7 (3.9) 
months for those with a BTVpreRCx above 9.5, p=0.002 and p=0.08 (Fig. 1 A-B). The 
prognostic impact of BTVpreRCx was independent of the applied mode of surgery and 
remained statistically significant in each of the cohorts. The prognostic/predictive 
impact of BTVpreRCx pertained also in the subgroup of 64 patients which completed the 
course of RCx (OS: p=0.007, PFS: p=0.13). Median BTVpreRCx  was significantly 
smaller in the resection group than in the biopsy group ( 0.8 and 20.1, p<0.0001); 
however, an overlapping distribution of the BTVpreRCx between the cohorts exists.  
In those with a BTVpreRCX below 9.5 ccm, the median Gd+ volume and Gd+volume 
including necrotic areas was 0.61 ccm (range: 0-29.6 ccm) and 1.81 ccm (range 0.0-
58.9 ccm), respectively. The corresponding values for those with a BTVpreRCX above 
9.5 ccm were 12.2 ccm (range 0.4-69.5 ccm) and 24.3 ccm (range 0.46-95.9 ccm), 
respectively. A similar distribution could be observed in biopsy group compared to 
resection group. 
In MRI before RCx, a smaller Gd+volume (without necrotic or cystic parts) was also 
associated with prolonged OS (p=0.006); Gd+volume plus necrotic tumor parts and 
T2/FLAIR estimated volume did not gain prognostic impact.  
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For patient examples of BTV in comparison to Gd+ volume , please see Figure 2. 
 
LBRmax and TAC before RCx 
Initial LBRmax values showed no association with PFS or OS in cohort A or B either 
considered separately or pooled. However, those with lower LBRmax(LBRmax-preRCx) 
values experienced longer PFS and OS. According to ROC analysis, the cut-point for 
LBRmax-preRCx was 2.9 for (SN 68%; SP 73%; p<0.0001, HR 2.9, for OS and p=0.01, 
HR 2.0, for PFS) (Fig. 1 C-D). 
The initial TAC pattern was associated with prognosis: patients exhibiting increasing 
TAC experienced longer OS (29.7 vs. 12.5 months; p=0.02, HR 2.1, Fig. 1E) and 
longer PFS (11.9 vs. 5.8 months; p=0.05, HR 1.8, Fig. 1F). LBRmax, BTV, and TAC 
were not correlated with age, KPS or MGMT promoter methylation status. 
LBRmaxvalues correlated positively with the corresponding BTV (Pearson‘s R= 0.6, 
p<0.001). 
 
BTV, LBRmaxand TAC after RCx 
LBRmax-preRCx and BTVpreRCx decreased after RCx from 3.7 to 2.4 (p<0.0001) and from 
28.8 to 12.4 ccm (p<0.0001). No further decrease was seen after 3 cycles of TMZ 
(Imaging biomarker dynamics are summarized in Table 1). Absolute and relative 
reduction of LBRmax-preRCx and BTVpreRCx after RCx did not relate to PFS and OS. Out 
of 53 patients in whom  PET after RCx was performed, TAC was available in 49 
patients (Supplemental Fig. e-2): TAC remained decreasing in 18 patients, changed 
from decreasing to increasing in 16 patients, remained increasing in 6 patients and 
changed from increasing to decreasing in 5 patients.  
A change from decreasing to increasing TAC was associated with longer PFS 
compared to patients in whom TAC pattern remained decreasing (6.5 vs. 3.4 months; 
p=0.017). Patients with a persistently increasing TAC had a longer PFS than those in 
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whom the pattern changed from increasing to decreasing (16.7 vs. 10.6 months, 
p=0.4, Figure 3). 
 
Multivariate analyses 
A methylated MGMT promoter status, higher initial KPS, young age, increasing initial 
TAC, smaller BTVpreRCX and LBRmax-preRCx values, and smaller Gd+volume were 
favorable prognostic/predictive co-variates for OS in one variable models. For PFS, it 
was a methylated MGMT promoter status, higher initial KPS, increasing TACpostRCX, 
lower BTVpreRCX and Gd+volume. Multivariately, small BTVpreRCx, increasing initial TAC 
and MGMT promoter methylation were associated with both longer PFS and OS. 
Additionally, higher KPS values were associated with longer OS. Results of univariale 
and multivariate models are detailed in Table 2. Nearly identical results were obtained 
for those undergoing a complete course of RCx (data not given, available on request).  
 
Discussion 
 
In the current prospective study, the biological tumor volume prior to radio-
chemotherapy (BTVpreRCx) turned out to be a powerful 18FET-PET-derived imaging 
biomarker: patients with smaller BTVpreRCx, either after biopsy or tumor resection, did 
significantly better in terms of OS and PFS, which remained true after adjustment for 
the effects of treatment, MGMT promoter methylation, and other patient- and tumor 
related factors. This finding confirms our initial hypothesis. In the biopsy group, the 
initial BTV (equivalent to the BTVpreRCx in this group) gained prognostic relevance 
whereas in the resection group this was detectable only for the postresection BTV 
(which is BTVpreRCx in this group). Since minimal BTVpreRCx is strongly linked to OS, 
maximal surgical reduction of the BTV seems to be essential in resectable tumors. 
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This might explain why the inital BTV in the surgery group did not gain any impact on 
outcome in contrast to the finding in the biopsy group. 
Interestingly, removal of only necrotic parts of the tumor volume seems not to alter the 
prognosis as MRI based Gd+ volume was also significantly associated with OS  while 
Gd+ volume including necrotic/cystic area and T2/FLAIR volume was not. This is in 
line with data from a previous multicenter study with MRI as the only imaging 
modality14. 
The optimal threshold for favorable/unfavorable BTV after biopsy/surgery still needs 
elucidation and could not be precisely resolved by the design of this and other 
studies9. However, a post-resection GD+volume of approximately 0 ccm in the surgery 
group can harbour a BTVpreRCx of up to 9.5 ccm. This might explain that survival in 
both cohorts was rather similar even though BTVpreRCx was lower in the surgery group. 
Only for those patients completing RCX, a moderate survival benefit was detected 
after surgery. This implies that BTV-based prognostic evaluation will refine indications 
for open tumor resection and biopsy in glioblastoma patients: in lesions which are not 
amenable for a safe and significant surgical reduction of the biologically relevant active 
tumor volume (which will not be achieved by removal of necrotic tissue only), the role 
of surgery might be questionable whereas patients with large BTVs and surgically 
accessible tumors might be good candidates for tumor resection. 
The association of the LBRmax-preRCx and outcome, although positively correlated with 
the respective BTV, was more heterogeneous; its impact was clearly dominated by the 
BTVpreRCx in multivariate models.  
 
The optimal time point for PET-guided assessment of treatment response after RCx of 
GBM patients remains unknown. We demonstrate that both BTV and LBRmax 
significantly decreased six weeks after RCx; however, with no prognostic threshold for 
these static measures. Unspecific 18FET uptake in treatment-induced reactive gliosis 
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might have confounded the discrimination between responders and non-responders in 
the current study15. Recently published studies showed conflicting results: a significant 
influence was found 6-8 weeks after RCx, however, this was not confirmed after a 
longer observation time16,17. Whether a PET scan 7-10 days after RCx is more reliable 
for the evaluation of treatment response has yet to be elucidated9. Yet, short time 
evaluation could interact with occurrence of pseudoprogression: as imaging was 
conducted after 6-8 weeks in our study, only two patients showed pseudoprogression 
in MRI. Interestingly, there was no correlating increase in BTV in those patients. This 
small number is in line with a recent publication examining the incidence of 
pseudoprogression18. Thus, future prospective studies should resolve uncertainties 
concerning appropriate time points for treatment response assessment by static 
18FET-PET analysis. 
We have previously demonstrated the prognostic value of 18FET kinetics in recurrent 
high-grade glioma19. Based on the present study, analysis of TAC and their changes 
during the disease course offers an additional imaging biomarker for early prognostic 
evaluation and assessment of treatment response. Initial TAC and TAC changes after 
RCx had prognostic influence on outcome. These results seem to contrast findings of 
a recent study where no influence was detected for several kinetic measures17. 
Notably, in the latter study comprising a small study population, TAC were evaluated 
in differently defined ROIs: pretherapeutic TAC were assessed within the tumor ROI 
corresponding to the target volume of radiotherapy, which was subsequently 
transferred to the coregistered slices of the follow-up PET for the analysis of 
posttherapeutic TAC. Therefore, the method of dynamic analysis, namely the ROI 
definition, seems to be essential for the assessment of the prognostic value. 
Furthermore, it remains subject to further investigations to elucidate whether tumors 
exhibiting increasing TAC differ in biology and/or vascularity from those with a 
decreasing pattern. FET uptake is influenced by the expression of amino acid 
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transporters as well as tumor perfusion20-22, however, the underlying mechanisms 
concerning the slope of the TAC remain to be explored.  
 
Our study has limitations: first, we did not apply RANO criteria since the study started 
prior to their publication23, 24. Second, evaluation of TAC was based on a relatively 
small sample size and deserves further evaluation. 
 
Altogether, 18FET-PET-derived imaging biomarkers before and after concomitant 
radio-/chemotherapy in GB are powerful tools to obtain prognostic information for 
outcome in newly diagnosed GBM. BTV as delineated by 18FET-PET before RCx/TMZ 
correlates with PFS and OS. Tumor uptake kinetic of 18FET is associated with PFS. 
These findings might help to individualize therapy and response evaluation in 
forthcoming clinical investigations. 
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Table 1. BTV, LBR and TAC values 
  
Value 
Initial 
PET 
PET 
after resection 
PET 
after RCx 
PET 
after TMZ 
All 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LBRmax 
mean 
median 
SD 
 
3.7 
3.6 
1.03 
  
2.4 (*) 
 2.3  
0.81  
 
2.3 (*) 
2.2 
0.94 
BTV (ccm) 
mean 
median 
SD 
 
28.8 
23.8 
22.8 
 
12.4 (*) 
4.8 
19.7 
 
11.7 (*) 
5.4  
16.78 
increasing TAC (patients) 15 26 7 
decreasing TAC (patients) 59 23 16 
Gd+ volume MRI (+necrosis) 
mean 
median 
SD 
 
42.9 
33.9 
37.0 
 
 
- 
 
 
- 
Gd+ volume MRI (-necrosis) 
mean 
median 
SD 
T2/FLAIR volume MRI 
mean 
median 
SD 
 
17.4 
13.5 
14.8 
 
86.1 
75.0 
51.7 
  
 
- 
 
 
- 
Cohort A LBRmax 
mean 
median 
SD 
 
3.8 
3.7 
1.15 
 
2.1 (*) 
2.0  
1.45 
 
2.1 (*) 
2.1  
0.75 
 
2.0 
2.0 
0.94 
BTV (ccm) 
mean 
median 
SD 
 
31.5 
24.8 
26.07 
 
3.1 (*) 
0.75 
5.87 
 
4.6 (*) 
1.8 
7.87 
 
10.1 
1.4 
17.71 
increasing TAC (patients) 8  15 14 8 
decreasing TAC (patients) 34 16  9 4 
Gd+ volume MRI (+necrosis) 
mean 
median 
SD 
 
53.7 
46.3 
43.2 
 
8.6(*) 
                0.6 
 13.8 
 
 
- 
 
 
- 
Gd+ volume MRI (-necrosis) 
mean 
median 
SD 
T2/FLAIR volume MRI 
mean 
median 
SD 
 
21.5 
21.3 
15.32 
 
104.7 
               87.9 
57.5 
 
2.1 (*) 
0.0 
3.76 
 
25.1(*) 
18.4 
21.8  
 
 
- 
 
 
- 
Cohort B LBRmax 
mean 
median 
SD 
 
3.6 
3.5 
0.86 
  
2.8 (*) 
2.5 
0.72  
 
2.9 (**) 
2.9 
0.67  
BTV (ccm) 
mean 
median 
SD 
 
25.8 
21.8 
17.5 
 
20.0 (**) 
10.7  
24.34  
 
13.9 (**) 
13.8  
15.97  
increasing TAC (patients) 8 9 8 
decreasing TAC (patients) 29 16 3 
Gd+ volume MRI (+necrosis) 
mean 
median 
SD 
 
32.5 
24.9 
26.2 
 
 
- 
 
 
- 
Gd+ volume MRI (-necrosis) 
mean 
median 
SD 
T2/FLAIR volume MRI 
    mean 
    median 
    SD 
 
 
13.7 
11.9 
13.47 
 
68.7 
66.5 
38.78 
  
 
- 
 
 
- 
Abbreviations: LBRmax, maximal lesion-to-brain ratio, BTV, biological tumor volume (determined by 18FET-PET), TAC, time activity 
curves, Gd+, gadolinium enhanced.  Legend: Wilcoxon test: *p <0.0001, **p<0.05; ()= comparison with values from the first column 
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Table 2. Results univariate/multivariate analysis 
Univariate Analysis of OS and PFS 
 Progression Death 
Factor Relative Risk 95% CI P 
Relative 
Risk 95% CI P 
MGMT promoter  
 Unmethylated 1.00   1.00   
 Methylated 0.40 0.23-0.71 .002 0.35 0.21-0.61 <.0001 
KPS* 0.97 0.94-1.00 .03 0.95 0.93-0.98 <.0001 
Age* 1.00 0.99-1.03 .16 1.03 1.01-1.05 .005 
Mode of surgery 
 Resection 0.86 0.52-1.43  0.73 0.45-1.17  
 Biopsy 1.00  .72 1.00  .19 
Initial TAC 
 increasing 1.00   1.00   
 decreasing 1.83 0.98-3.41 .06 2.05 1.10-3.83 .02 
TACPOSTRCx 
 increasing 0.46 0.25-0.84 .01 0.9 0.74-1.30 .9 
 decreasing 1.00   1.00   
BTVPRERCx* 1.02 1.01-1.04 .03 1.03 1.01-1.05 <.0001 
LBRmax-PRERCx* 1.19 0.94-1.50 .15 1.38 1.12-1.69 .002 
Gd+MRI Volume* 1.02 1.00-1.05 .03 1.03 1.01-1.05 .006 
NOTE. * continuously scaled ; KPS 10 points increment 
Abbreviations: MGMT: O6-methylguanyl-DNA-methyltransferase, KPS, Karnofsky performance score, TAC, 
time activity curves, BTV, biological tumor volume (determined by 18FET-PET), LBRmax, maximal lesion-to-
brain ratio, preRCX, before radiochemotherapy, postRCx, after radiochemotherapy, Gd+, Gadolinium 
enhanced 
Multivariate Analysis of OS and PFS 
 Progression Death 
Factor Relative Risk 95% CI P 
Relative 
Risk 95% CI P 
MGMT promoter   
 Unmethylated 1.00   1.00  <.0001 
 Methylated 0.45 0.27-0.80 .007 0.27 0.15-0.49  
KPS* 0.98 0.95-1.0 .06 0.96 0.93-0.98 <.0001 
Initial TAC  
 increasing 1.00      
 decreasing 1.92 0.98-3.76 .06 2.03 1.05-3.90 .035 
BTVPRERCx* 1.02 1.00-1.04 .018 1.03 1.01-1.05 <.0001 
NOTE. * continuously scaled; KPS 10 points increment, Abbreviations: ns, not significant, MGMT: O6-methylguanyl-
DNA-methyltransferase, KPS, Karnofsky performance score, TAC, time activity curves, BTV, biological tumor 
volume (determined by 18FET-PET), preRCX, before radiochemotherapy 
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Figure 1 A-F: Association of BTVpreRCx (A/B), LBRmax-preRCx (C/D) and initial TAC (E/F) with OS and PFS
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Fig. 3: Patient examples: (A) Patient with a favourable outcome (OS xx months) with an initial BTV of 
xx ccm, Gd+ volume (-necrosis) of xx ccm. (B) Patient with an unfourable outcome (OS xx months) 
with an initial BTV of xx ccm and Gd+ volume (- necrosis ) of xx ccm. 
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